Sareum Holdings (GB:SAR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sareum Holdings PLC, a biotech firm focused on developing kinase inhibitors for autoimmune diseases and cancer, has announced its Annual General Meeting to be held on December 19, 2024, in London. The company, which trades under the ticker SAR on the AIM market, will also provide online access to the AGM for shareholders via the Investor Meet Company platform. Sareum’s leading candidate, SDC-1801, has completed Phase 1 clinical development, showcasing potential in treating autoimmune diseases.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
